Liminatus Pharma, Inc. Class A Common Stock (LIMN) NASDAQ
0.19
+0.0073(+4.06%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
0.19
+0.0073(+4.06%)
Currency In USD
| Market Cap | 14.49M |
| Enterprise Value | 15.59M |
| P/E Ratio | -0.49 |
| PEG Ratio | 0.07 |
| Price/Sales Ratio | 0 |
| Price/Book Ratio | -0.49 |
| Enterprise/Revenue | 0 |
| Enterprise/EBITDA | -0.67 |
| Fiscal Year | December 31, 2025 |
| Most Recent Quarter | December 31, 2025 |
| Profit Margin | 0 |
| Operating Margin | 0 |
| Return On Assets | -19.27 |
| Return On Equity | 1.95 |
| Revenue | 0 |
| Revenue/Share | 0 |
| Gross Profit | 0 |
| EBITDA | -9.99M |
| Net Income | -10.21M |
| Diluted EPS | -0.43 |
| Total Cash | 337,655 |
| Total Cash/Share | 0.01 |
| Total Debt | 1.44M |
| Total Debt/Equity | -0.15 |
| Current Ratio | 0.05 |
| Book Value Per Share | -0.41 |
| 52-Week Change | -95.96 |
| 52-Week High | 33.66 |
| 52-Week Low | 0.16 |
| Moving Average 50 Days | 0.4 |
| Moving Average 200 Days | 2.01 |
| Average Volume | 9.22M |
| Shares Outstanding | 26.83M |
| % Held by Institutions | N/A |
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0 |
| Payout Ratio | 0 |
| Last Split Factor | N/A |
| Last Split Date | N/A |